

International Nonproprietary Names for Pharmaceutical Substances (INN)

RECOMMENDED International Nonproprietary Names: List 57

Notice is hereby given that, in accordance with paragraph 7 of the Procedure for the Selection of Recommended International Nonproprietary Names for Pharmaceutical Substances [*Off. Rec. Wild Health Org.*, 1955, **60**, 3 (Resolution EB15.R7); 1969, **173**, 10 (Resolution EB43.R9)], the following names are selected as Recommended International Nonproprietary Names. The inclusion of a name in the lists of Recommended International Nonproprietary Names does not imply any recommendation of the use of the substance in medicine or pharmacy.

Lists of Proposed (1–91) and Recommended (1–52) International Nonproprietary Names can be found in *Cumulative List No. 11, 2004* (available in CD-ROM only).

Dénominations communes internationales des Substances pharmaceutiques (DCI)

Dénominations communes internationales RECOMMANDÉES: Liste 57

Il est notifié que, conformément aux dispositions du paragraphe 7 de la Procédure à suivre en vue du choix de Dénominations communes internationales recommandées pour les Substances pharmaceutiques [*Actes off. Org. mond. Santé*, 1955, **60**, 3 (résolution EB15.R7); 1969, **173**, 10 (résolution EB43.R9)] les dénominations ci-dessous sont choisies par l'Organisation mondiale de la Santé en tant que dénominations communes internationales recommandées. L'inclusion d'une dénomination dans les listes de DCI recommandées n'implique aucune recommandation en vue de l'utilisation de la substance correspondante en médecine ou en pharmacie.

On trouvera d'autres listes de Dénominations communes internationales proposées (1–91) et recommandées (1–52) dans la *Liste récapitulative No. 11, 2004* (disponible sur CD-ROM seulement).

Denominaciones Comunes Internacionales para las Sustancias Farmacéuticas (DCI)

Denominaciones Comunes Internacionales RECOMENDADAS: Lista 57

De conformidad con lo que dispone el párrafo 7 del Procedimiento de Selección de Denominaciones Comunes Internacionales Recomendadas para las Sustancias Farmacéuticas [*Act. Of. Mund. Salud*, 1955, **60**, 3 (Resolución EB15.R7); 1969, **173**, 10 (Resolución EB43.R9)], se comunica por el presente anuncio que las denominaciones que a continuación se expresan han sido seleccionadas como Denominaciones Comunes Internacionales Recomendadas. La inclusión de una denominación en las listas de las Denominaciones Comunes Recomendadas no supone recomendación alguna en favor del empleo de la sustancia respectiva en medicina o en farmacia.

Las listas de Denominaciones Comunes Internacionales Propuestas (1–91) y Recomendadas (1–52) se encuentran reunidas en *Cumulative List No. 11, 2004* (disponible sólo en CD-ROM).

Latin , English, French, Spanish: <i>Recommended INN</i>	<i>Chemical name or description; Molecular formula; Graphic formula</i>
<i>DCI Recommandée</i>	<i>Nom chimique ou description; Formule brute; Formule développée</i>
<i>DCI Recomendada</i>	<i>Nombre químico o descripción; Fórmula molecular; Fórmula desarrollada</i>

abagovomabum*
abagovomab

immunoglobulin G1, anti-idiotyp anti-[anti-(*Homo sapiens* cancer antigen 125, CA 125, MUC-16) *Mus musculus* monoclonal antibody OC125] *Mus musculus* monoclonal antibody ACA125, clone 3D5 gamma1 heavy chain disulfide with clone 3D5 kappa light chain; (223-223":226-226":228-228") trisulfide dimer

abagovomab

immunoglobuline G1, anti-idiotyp anti-[anti-(*Homo sapiens* cancer antigen 125, CA 125, MUC-16) anticorps monoclonal murin OC125] anticorps monoclonal murin ACA125, chaîne lourde gamma1 du clone 3D5 unie par un pont disulfure à la chaîne légère kappa du clone 3D5; dimère (223-223":226-226":228-228")-trisulfure

abagovomab

immunoglobulina G1, anti-idiotipo anti-[anti-(*Homo sapiens* cancer antígeno 125, CA 125, MUC-16) anticuerpo monoclonal murino OC125] anticuerpo monoclonal murino ACA125, cadena pesada gamma1 del clon 3D5 unida por un puente disulfuro a la cadena ligera kappa del clon 3D5; dímero (223-223":226-226":228-228")-trisulfuro

Heavy chain/Chaîne lourde/Cadena pesada

QVKLQESGAE	LARPGASVKL	SCKASGYTFT	NYWMQWVKQR	PGQGLDWIGA	50
IYPGDGNTRY	THKFKGKATL	TADKSSSTAY	QMLSSLASED	SGVYYCARGE	100
GNYAWFAYWG	QGTITVTVSSA	KTTPPSVYPL	APGSAAQTN	MVTLGCLVKG	150
YFPEPVTVTW	NSGSLSSGVH	TFPAVLQSDL	YTLSSSVTV	SSTWPSSETV	200
CNVAHPASST	KVDKIKIVPRD	CGCKPCICTV	PEVSSVFIFP	PKPKDVLITIT	250
LTPKVTCTVV	DISKDDPEVQ	FSWFVDDVEV	HTAQTQPREE	QFNSTFRSVS	300
ELPIMHQDWL	NGKEFKCRVN	SAAFPAPIEK	TISKTKGRPK	APQVYTIPPP	350
KEQMAKDKVS	LTCMIDTFPP	EDITVEWQWN	GQPAENYKNT	QPIMDTDGSY	400
FVYSKLNQVK	SNWEAGNTFT	CSVLHEGLHN	HHTKSLSHS	PGK	443

Light chain/Chaîne légère/Cadena ligera

DIELTQSPAS	LSASVGETVT	ITCQASENIY	SYLAWHQQKQ	GKSPQLLVYN	50
AKTLAGVSS	RFGSGSGGTH	FSLKIKSLQP	EDFGIYYCQH	HYGILPTFGG	100
GTKLEIKRAD	AAPTYSIFPP	SSEQLTSGGA	SVVCFLNPFY	PKDINVKWKI	150
DGSRQNGVL	NSWTDQDSKD	STYSMSSTLT	LTKDEYERHN	SYTCEATHKT	200
STSPIVKSFN	RNEC				214

acidum iodofilticum (¹²³I)
iodofiltic acid (¹²³I)

(3*RS*)-15-[4-¹²³I]iodophenyl]3-methylpentadecanoic acid


acide iodofiltique (¹²³I)

acide (3*RS*)-15-(4-¹²³I]iodophényl)-3-méthylpentadécanoïque

ácido iodofíltico (¹²³I)

ácido (3*RS*)-15-(4-¹²³I]iodofenil)-3-metilpentadecanoico

C₂₂H₃₅¹²³IO₂



aclidinii bromidum


aclidinium bromide

(3*R*)-3-[(hydroxy)di(thiophen-2-yl)acetyloxy]-1-(3-phenoxypropyl)-1λ⁵-azabicyclo[2.2.2]octan-1-ylum bromide

bromure d'aclidinium

bromure de (3*R*)-3-[[hydroxybis(thiophén-2-yl)acétyl]oxy]-1-(3-phénoxypropyl)-1-azoniabicyclo[2.2.2]octane

bromuro de aclidinio

bromuro de (3*R*)-1-(3-fenoxipropil)-3-[(hidroxi)di(tiofen-2-il)acetiloxi]-1λ⁵-azabicio[2.2.2]octan-1-ilioC₂₆H₃₀BrNO₄S₂**afimoxifenum**

afimoxifene


4-(1-[4-[2-(dimethylamino)ethoxy]phenyl]-2-phenylbut-1-enyl)phenol

afimoxifène

4-[1-[4-[2-(diméthylamino)éthoxy]phényl]-2-phénylbut-1-ényl]phénol

afimoxifeno

4-[1-[4-[2-(dimetilamino)etoxi]fenil]-2-fenilbut-1-enil]fenol


C₂₆H₂₉NO₂and Z isomer
et l'isomère Z
y el isómero Z**afiberceptum***

afibercept

des-432-lysine-[human vascular endothelial growth factor receptor 1-(103-204)-peptide (containing Ig-like C2-type 2 domain) fusion protein with human vascular endothelial growth factor receptor 2-(206-308)-peptide (containing Ig-like C2-type 3 domain fragment) fusion protein with human immunoglobulin G1-(227 C-terminal residues)-peptide (Fc fragment)], (211-211':214-214')-bisdisulfide dimer

afibercept

(211-211':214-214')-bisdisulfure du dimère de la dès-432-lysine-[récepteur 1 humain du facteur de croissance endothélial vasculaire-(103-204)-peptide (contenant le domaine Ig-like C2-type 2) protéine de fusion avec le récepteur 2 humain du facteur de croissance endothélial vasculaire-(206-308)-peptide (contenant un fragment du domaine Ig-like C2-type 3) protéine de fusion avec l'immunoglobuline G1 humaine-(227 résidus C-terminaux)-peptide (fragment Fc)]

affibercept	(211-211':214-214')-bisdisulfuro del dímero de la des-432-lisina-[receptor 1 humano del factor de crecimiento endotelial vascular-(103-204)-péptido (que contiene el dominio Ig-like C2-tipo 2) proteína de fusión con el receptor 2 humano del factor de crecimiento endotelial vascular-(206-308)-péptido (que contiene un fragmento del dominio Ig-like C2-tipo 3) proteína de fusión con la inmunoglobulina G1 humana-(227 restos C-terminales)-péptido (fragmento Fc)]
	C ₄₃₁₈ H ₆₇₈₈ N ₁₁₆₄ O ₁₃₀₄ S ₃₂
	<p>Monomer / Monomère / Monómero</p> <pre> SDTGRPFVEM YSEIPEIIHM TEGRELVIPC RVTSPNITVT LKKFPLDTLI 50 PDGKRIIWDS RKGFLIISNAT YKEIGLLTCE ATVNGHLYKT NYLTHRQTNT 100 IIDVLSPSH GIELSVGKEL VLNCTARTEL NVGIDFNWEY PSSKHQHKKL 150 VNRDLKTQSG SEMKKFLSTL TIDGVTRSDQ GLYTCAASSG LMTKKNSTFV 200 RVHEKDKTHT CPPCPAPELL GGPSVFLFPQ KPKDTLMISR TPEVTCVVVD 250 VSHEDPEVKF NWYVDGVEVH NAKTKPREEQ YNSTYRVVSV LTVLHQDWLN 300 GKEYKCKVSN KALPAPIEKT ISKAKGQPRE PQVYTLPPSR DELTKNQVSL 350 TCLVKGFYPS DIAVEWESNG QPENNYKTFP PVLDSGDSFF LYSKLTVDKS 400 RWQQGNVPSV SVMHEALHNS YTKKSLSLSP G 431 </pre>
	<p>Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro</p> <p>30-79 30'-79' 124-185 124'-185' 211-211' 214-214' 246-306 246'-306' 352-410 352'-410'</p>
aleglitazarum	
aleglitazar	(2S)-2-methoxy-3-[4-[2-(5-methyl-2-phenyl-1,3-oxazol-4-yl)ethoxy]-1-benzothiophen-7-yl]propanoic acid
aléglitazar	acide (2S)-2-méthoxy-3-[4-[2-(5-méthyl-2-phényl-1,3-oxazol-4-yl)éthoxy]-1-benzothiophén-7-yl]propanoïque
aleglitazar	ácido (2S)-3-[4-[2-(2-fenil-1,3-oxazol-5-metil-4-il)etoxi]-1-benzotiofen-7-il]-2-metoxipropanoico
	C ₂₄ H ₂₃ NO ₅ S
	
alferminogenum tadenovecum*	
alferminogene tadenovec	recombinant human adenovirus 5 (replication-deficient, E1-deleted) containing a human fibroblast growth factor-4 cDNA sequence driven by a cytomegalovirus promoter
alferminogène tadénovec	adénovirus 5 humain recombinant (réplication-déficient, région E1-supprimée) contenant la séquence ADN-copie du facteur 4 de croissance du fibroblaste humain sous contrôle d'un promoteur de cytomégalovirus
alferminogén tadenovec	adenovirus 5 humano recombinante (replicación-deficiente, con delección E1) que contiene la secuencia DNA-copia del factor-4 de crecimiento de fibroblastos humanos controlado por un promotor de citomegalovirus

apilimodum

apilimod


1-[(3-methylphenyl)methylidene]-2-[6-(morpholin-4-yl)-2-[2-(pyridin-2-yl)ethoxy]pyrimidin-4-yl]hydrazine

apilimod

1-(3-méthylbenzylidène)-2-[6-(morpholin-4-yl)-2-[2-(pyridin-2-yl)éthoxy]pyrimidin-4-yl]diazane

apilimod

1-(3-metilbencilideno)-2-[6-(morfolin-4-il)-2-[2-(piridin-2-il)etoksi]=pirimidin-4-il]diazano

C₂₃H₂₆N₆O₂**apricitabinum**


apricitabine

4-amino-1-[(2*R*,4*R*)-2-(hydroxymethyl)-1,3-oxathiolan-4-yl]pyrimidin-2(1*H*)-one

apricitabine

(-)-4-amino-1-[(2*R*,4*R*)-2-(hydroxyméthyl)-1,3-oxathiolan-4-yl]=pyrimidin-2(1*H*)-one

apricitabina

(-)-4-amino-1-[(2*R*,4*R*)-2-(hidroximetil)-1,3-oxatiolan-4-il]pirimidin-2(1*H*)-onaC₈H₁₁N₃O₃S**artemisonum**

artemisine


4-[(3*R*,5*aS*,6*R*,8*aS*,9*R*,10*R*,12*R*,12*aR*)-3,6,9-trimethyldecahydro-12*H*-3,12-epoxyprano[4,3-*j*][1,2]benzodioxepin-10-yl]=thiomorpholine-1,1-dione

artémisone

1,1-dioxyde de 4-[(3*R*,5*aS*,6*R*,8*aS*,9*R*,10*R*,12*R*,12*aR*)-3,6,9-triméthyldécahydro-3,12-époxyprano[4,3-*j*]-1,2-benzodioxépin-10-yl]thiomorpholine

artemisona

1,1-dióxido de 4-[(3*R*,5*aS*,6*R*,8*aS*,9*R*,10*R*,12*R*,12*aR*)-3,6,9-trimetildécahidro-3,12-epoxipirano[4,3-*j*]-1,2-benzodioxepin-10-il]=tiomorfolina

C₁₉H₃₁NO₆S

ataceptum*
atacept

[86-serine,101-glutamic acid,196-serine,197-serine,222-aspartic acid,224-leucine][human tumor necrosis factor receptor superfamily member 13B-(30-110)-peptide (TAC1 fragment containing TNFR-Cys 1 and TNFR-Cys 2) fusion protein with human immunoglobulin G1-(232 C-terminal residues)-peptide (γ1-chain Fc fragment), (92-92':95-95')-bisdisulfide dimer

atacept

(92-92':95-95')-bisdisulfure du dimère de la [86-sérine,101-acide glutamique,196-sérine,197-sérine,222-acide aspartique,224-leucine]-protéine de fusion du membre 13B humain de la superfamille des récepteurs du facteur de nécrose tumorale-(30-110)-peptide (portion du TAC1 incluant les deux régions riches en cystéine) avec l'immunoglobuline G1 humaine-(232 résidus C-terminaux)-peptide (fragment Fc de la chaîne γ1)

atacept

92-92':95-95')-bisdisulfuro del dímero de la [86-serina,101-ácido glutámico,196-serina,197-serina,222-ácido aspártico,224-leucina]-proteína de fusión del miembro 13B humano de la superfamilia de receptores del factor de necrosis tumoral-(30-110)-péptido (porción del TAC1 que incluye las dos regiones ricas en cisteína) con la inmunoglobulina G1 humana-(232 restos C-terminales)-péptido (fragmento Fc de la cadena γ1)

C₃₁₀₄H₄₇₈₈N₈₅₆O₉₅₀S₄₄

Monomer / Monomère / Monómero				
AMRSCPPEEQY	WDPLLGTCMS	CKTICNHQSQ	RTCAAFCRSL	SCRKEQGKPFY 50
DHLRLDCISC	ASICGQHPKQ	CAYFCENKLR	SEPKSSDKTH	TCPPCPAPEA 100
EGAPSVFLFP	PKPKDTLMIS	RTPEVTCVVV	DVSHEDPEVK	FNWVVDGVEV 150
HNAKTKPREE	QYNSTYRVVS	VLTVLHQDWL	NGKEYKCKVS	NKALPSSIEK 200
TISKAKGQFR	EPQVYTLPPS	RDELTKNQVS	LTCLVKGFPY	SDIAVWESN 250
QPENNYKTT	PPVLDSDGSF	FLYSKLTVDK	SRWQQGNVFS	CSVMHEALHN 300
HYTQKSLSL	PGK			313

Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro
 5-18 5'-18' 21-33 21'-33' 25-37 25'-37' 42-57 42'-57' 60-71
 60-71' 64-75 64'-75' 92-92' 95-95' 127-187 127'-187' 233-291 233'-291'

azilsartanum
azilsartan



2-ethoxy-1-[[2'-(5-oxo-4,5-dihydro-1,2,4-oxadiazol-3-yl)-1,1'-biphenyl-4-yl]methyl]-1H-benzimidazole-7-carboxylic acid

azilsartan

acide 2-éthoxy-1-[[2'-(5-oxo-4,5-dihydro-1,2,4-oxadiazol-3-yl)-biphényl-4-yl]méthyl]-1H-benzimidazole-7-carboxylique

azilsartán

ácido 2-etoxi-1-[[2'-(5-oxo-4,5-dihidro-1,2,4-oxadiazol-3-il)bifenil-4-il]metil]-1H-bencimidazol-7-carboxílico

**bavituximabum***

bavituximab


immunoglobulin G1, anti-(phosphatidylserine) chimeric monoclonal ch3G4; gamma1 heavy chain (*Mus musculus* VH-*Homo sapiens*IGHG1) (223-214')-disulfide with kappa light chain (*Mus musculus* V-KAPPA-*Homo sapiens* IGKC); (229-229':232-232'')-bisdisulfide dimer

bavituximab

immunoglobuline G1, anti-(phosphatidylsérine) anticorps monoclonal chimérique ch3G4; chaîne lourde gamma1 (*Mus musculus* VH-*Homo sapiens* IGHG1) (223-214')-disulfure avec la chaîne légère kappa (*Mus musculus* V-KAPPA-*Homo sapiens* IGKC); dimère (229-229'':232-232'')-bisdisulfure

bavituximab

inmunoglobulina G1, anti-(fosfatidilserina) anticuerpo monoclonal quimérico ch3G4; cadena pesada gamma1 (*Mus musculus* VH-*Homo sapiens* IGHG1) (223-214')-disulfuro con la cadena ligera kappa (*Mus musculus* V-KAPPA-*Homo sapiens* IGKC), dímero (229-229'':232-232'')-bisdisulfuro



Heavy chain / Chaîne lourde / Cadena pesada


EVQLQSSGPE	LEKPGASVKL	SCKASGYST	GYNMNWKQS	HGKLEWIGH	50
IDPYYGDTSY	NQKFRGKATL	TVDKSSSTAY	MLKSLTSED	SAVYYCVKGG	100
YFGHWYFDVW	GAGTTVTVSS	ASTKGPSVFP	LAPSSKSTSG	GTAALGCLVK	150
DYFPEPVTVS	WNSGALTSKV	HTFPAVLQSS	GLYSLSVVT	VPSSSLGTQT	200
YICNVNPKPS	NTKVDKKEP	KSCDKTHTCP	PCPAPPELLGG	PSVFLPPEPK	250
KDTLMISRTP	EVTQVVDVDS	HEDEPKVFNW	YVDGVEVHNA	KTKPREEQYN	300
STYRVVSVLT	VLHQDWLNGK	EYKCKVSNKA	LPAPIEKTIS	KAKGQPRFPQ	350
VYTLPPSRDE	LTKNQVSLTC	LVKGFYPSDI	AVEWESNGQP	ENNYKTTTPV	400
LDSDGSFFLY	SKLTVDKSRW	QQGNVFSQSV	MHEALHNHYT	QKSLSLSPGK	450


k Chain / Chaîne k / Cadena k

DIQMTQSPSS	LSASLGERVS	LTCRASQDIG	SSLNWLQQGP	DGTIKRLIYA	50'
TSSLDSGVPK	RFGSRSRSGSD	YSLTISLES	EDFVDYYCLQ	YVSSPPTFGA	100'
GTKLELKRAD	AAPSVFIFPP	SDEQLKSGTA	SVVCLLNNFY	FREAKVQWKV	150'
DNALQSGNSQ	ESVTEQDSKD	STYLSLSTLT	LSKADYEKHK	VYACEVTHQG	200'
LSSPVTKSFN	RGEC				214'

Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro

22-96 22'-96" 23'-88" 23"-88" 134'-194' 134"-194" 147-203 147"-203"
214'-223 214"-223" 229-229" 232-232" 264-324 264'-324" 370-428 370"-428"

bedoradrinum bedoradrine	2-[[[(7 <i>S</i>)-7-[[[(2 <i>R</i>)-2-hydroxy-2-[4-hydroxy-3-(2-hydroxyethyl)phenyl]=ethyl]amino]-5,6,7,8-tetrahydronaphthalen-2-yl]oxy]- <i>N,N</i> -dimethylacetamide
bédoradrine	(-)-2-[[[(7 <i>S</i>)-7-[[[(2 <i>R</i>)-2-hydroxy-2-[4-hydroxy-3-(2-hydroxyéthyl)=phényl]éthyl]amino]-5,6,7,8-tétrahydronaphtalén-2-yl]oxy]- <i>N,N</i> -diméthylacétamide
bedoradrina	(-)-2-[[[(7 <i>S</i>)-7-[[[(2 <i>R</i>)-2-hidroxi-2-[4-hidroxi-3-(2-hidroxietil)fenil]=etil]amino]-5,6,7,8-tetrahidronaftalen-2-il]oxi]- <i>N,N</i> -dimetilacetamida
	$C_{24}H_{32}N_2O_5$
	
beperminogenum perplasmidum* beperminogene perplasmid	plasmid DNA containing human hepatocyte growth factor cDNA sequence driven by a cytomegalovirus promoter
béperminogène perplasmide	ADN plasmidique contenant la séquence ADN-copie du facteur de croissance de l'hépatocyte humain sous contrôle d'un promoteur de cytomegalovirus
beperminogén perplásmido	DNA de plásmido que contiene la secuencia DNA-copia del factor de crecimiento del hepatocito humano controlado por un promotor de citomegalovirus
beroctocogum alfa* beroctocog alfa	human blood-coagulation factor VIII-(1-740)-peptide complex with human blood-coagulation factor VIII-(1649-2332)-peptide
béroctocog alfa	combinaison du facteur VIII de coagulation humain-(1-740)-peptide (chaîne lourde du facteur VIIIa, isoforme de 92 kDa) avec le facteur VIII de coagulation humain-(1649-2332)-peptide (chaîne légère du facteur VIIIa)
beroctocog alfa	combinación del factor VIII de coagulación humano-(1-740)-péptido (cadena pesada del factor VIIIa, isoforma de 92 kDa) con el factor VIII de coagulación humano-(1649-2332)-péptido (cadena ligera del factor VIIIa)



Heavy chain / Chaîne lourde / Cadena pesada

ATRRYYLGAV	ELSWDYMQSD	LGELPVDARF	PPRVPKSFPF	NTSVVYKCTL	50
FVEFTDHLFN	IAKRPPPMWG	LLGPTIQAEV	YDTVVITLKN	MASHPVSLHA	100
VGVSYWKASE	GAEYDDQTSQ	REKEDDKVFP	GGSHYYVWQV	LKENGPMASD	150
PLCLTYSYLS	HVDLVKDLNS	GLIGALLVCR	EGSLAKEKTO	TLHKFILLFA	200
VPDEGKSWHS	ETKNSLMQDR	DAASARAWPK	MHTVNGYVNR	SLPFLIGCHR	250
KSVYWHVIGM	GTTPVHVSIF	LEGHTFLVRN	HRQASLEISP	ITFLTAQTLL	300
MDLGQFLFC	HISSHQHDGM	EAYVKVDSQP	EEPQLRMKN	EEAEDYDDL	350
TDSEMDVVRP	DDDNSPSFIQ	IRSVAKKHPK	TWVHYIAAEE	EDWDYAPLVL	400
APDRRSYKSK	YLNNGPQRIQ	RKYKVRPFMA	YTDETFKTR	AIQHESGILG	450
PLLYGEGVDT	LLIIFKNQAS	RPYNIYPHGI	TDVRLYSRR	LPKGVKHLKD	500
FPLLPGEIFK	YKWTVTVEDG	PTKSDPRCLT	RYSSSFVNME	RDLASGLIGP	550
LLICYKESVD	QRGNQIMSDK	RNVILFSVFD	ENRSWYLTEN	IQRFPLNFBAG	600
VQLEDPEFQA	SNIMHSINGY	VFDSLQLSVC	LHEVAYWYIL	SIGAQTDFLS	650
VVFSGYTFKH	KMVYEDTLTL	FPFSGETVFM	SMENPGLWIL	GCHNSDFRNR	700
GMTALLKVSS	CDKNTGDYEE	DSYEDISAYL	LSKNNAIEPR	S	741

Light chain / Chaîne légère / Cadena ligera

TRTTLQSDQE	EIDYDDTISV	EMKKEDFDIY	DEDENQSPRS	FQKKTRHYFI	1650
AAVERLWDYG	MSSSPHVLRN	RAQSGSVQPF	KKVVFQEFDD	GSFTQPLVRG	1750
ELNEHLGLLG	PYIRAEVEDN	IMVTFRNQAS	RPYSFYSSLI	SYEEDQRQGA	1800
EPKRNFKVKN	ETKTYFWKVQ	HMAPTKDEF	DCKAWAYFSD	VLEKDVHSG	1850
LIGPLLVCHT	NLNLPAHGRQ	VTVQEPALFF	TIFDETKSWY	FTENMERNCR	1900
APCNIQMEDP	TFKENYRPHA	INGYIMDTLP	GLVMAQDQRI	RWYLLSMGNS	1950
ENIHSIHFSG	HVPTVRKKEE	YKMALYNLYP	GVFETVEMLP	SKAGIWRVEC	2000
LIGELHLHAGM	STLFLVYSNK	QOTPLGMASG	HIRDFQITAS	GQYQWAPKL	2050
ARLHYSGSIN	AWSTKEPFSW	IKVDLAPMI	IHGKIQGAR	QKFSLSYISQ	2100
FIIMYSLDCK	KWQTYRGNST	GTLMVFFGNV	DSSGKHNIF	NPPIIARYIR	2150
LHPTHYSIRS	TLRMEIMGCD	LNSCSMPLGM	ESKAISDAQI	TASSYFTNMF	2200
ATWSPSKARL	HLQGRSNAWR	PQVNNPKEWL	QVDFQKTMKV	TGVTTCQVKS	2250
LLTSMYVKEF	LISSSQDGHQ	WTLFFQNGKV	KVFFQGNQDSF	TPVNVSLDPP	2300
LLTRYLRIRP	QSWVHQIALR	MEVLGCEAQD	LY		2332

Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro
153-179 528-554 1899-1903 2021-2169 2174-2326

Glycosylation sites / Sites de glycosylation / Posiciones de glicosilación

Asn-41 Asn-239 Asn-582 Asn-1810 Asn-2118

Modifications / Modificaciones

Y = 4-O-sulfotyrosyl

bremelanotidum

bremelanotide



2,7-anhydro(*N*-acetyl-L-2-aminohexanoyl-L-aspartyl-L-histidyl-D-phenylalanyl-L-arginyl-L-tryptophyl-L-lysine)

brémelanotide

N-acétyl-L-2-aminohexanoil-L- α -aspartyl-L-histidyl-D-phénylalanyl-L-arginyl-L-tryptophyl-L-lysine-(2→7)-lactame

bremelanotida

N-acetil-L-2-aminohexanoil-L- α -aspartil-L-histidil-D-fenilalanil-L-arginil-L-triptofil-L-lisina-(2→7)-lactama



bucelipasum alfa* bucelipase alfa	human bile-salt-activated lipase (cholesterol esterase, EC 3.1.1.13), glycoform alfa (recombinant hBSSL)
bucélipase alfa	lipase activée par les sels biliars humaine (cholestérol estérase, EC 3.1.1.13), glycoforme alpha (recombinante hBSSL)
bucelipasa alfa	lipasa humana activada por las sales biliars (colesterol esterasa, EC 3.1.1.13), glicofoma alfa (recombinante hBSSL)

C₃₄₃₄H₅₂₅₈N₈₉₄O₁₀₄₁S₁₇


AKLGAVYTEG	GFVEGVNKKL	GLLGDSVDIF	KGIPFAAPTK	ALENPQPHFG	50
WQGTLLKAKNF	KKRCLQATIT	QDSTYGDEDC	LYLNIWVPGG	RKQVSRDLFV	100
MIWIYGGAFLL	MGSGLGANFL	NNLYDGEEI	ATRGNVIVVT	FNRYVGLPLGF	150
LSTGDANLPG	NYGLRDQHMA	IAWVKRNIAA	FGGDPNNITL	FGESAGGASV	200
SLQTLSPYNK	GLIRRAISQS	GVALSPWVIQ	KNPLFWAKKV	AEKVGCPVGD	250
AARMAQCCLKV	TDPRALTLAY	KVPLAGLEYP	MLHYVGFVPV	IDGDFIPADP	300
INLYANAADI	DYIAGTNMMD	GHFASIDMP	AINKGNKKVT	EEDFYKLVSE	350
FTITKGLRGA	KTTFDVYTES	WAQDPSQENK	KKTVVDFETD	VLFLVPTAIA	400
LAQHRANAKS	AKTYAYLFHS	PSRMPVYPKW	VGADHADDIQ	VYFGKPFATP	450
TGYRPODRTV	SKAMIAYWTN	FAKTGDPNMG	DSAVPTHWEP	YTTENSGYLE	500
ITKKMGSSSM	KRSLRTNFLR	YWTLYLALP	TVTQDEATPV	PPTGDSGATP	550
VPPTGDSETA	PVPPTGDSGA	PVPPTGDSG	APPVPTGDS	GAPPVPTGD	600
SGAPPVPTG	DSGAPPVPT	GDSGAPPVPP	TGDSGAPPVP	PTGDAGPPPV	650
PPTGDSGAPP	VPTGDSGAP	PVPTGDSSET	APVPTGDSG	APPVPTGDS	700
EAAPVPTDD	SKEAQMPAVI	RF			722

Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro
64-80 246-257


Glycosylation sites / Sites de glycosylation / Posiciones de glicosilación

Asn-187 Thr-538 Thr-549 Thr-559 Thr-576 Thr-587
Thr-598 Thr-609 Thr-620 Thr-631 Thr-642

camobucolum camobucol	4-{4-[(2-[[3,5-di(<i>tert</i> -butyl)-4-hydroxyphenyl]sulfanyl)propan-2-yl]=sulfanyl]-2,6-di(<i>tert</i> -butyl)phenoxy}acetic acid
camobucol	acide 4-{4-[(2-[[3,5-di(<i>tert</i> -butyl)-4-hydroxyphényl]sulfanyl)propan-2-yl]sulfanyl]-2,6-di(<i>tert</i> -butyl)phénoxy}acétique
camobucol	ácido 4-{4-[(2-[[3,5-di(<i>tert</i> -butil)4-hidroxfenil]sulfanil]propan-2-il)=sulfanil]-2,6-di(<i>tert</i> -butil)fenoxi}acético

C₃₃H₅₀O₄S₂

capadenosum capadenoson	2-amino-6-([2-(4-chlorophenyl)-1,3-thiazol-4-yl]methyl)sulfanyl]-4-[4-(2-hydroxyethoxy)phenyl]pyridine-3,5-dicarbonitrile
capadénoson	2-amino-6-[[[2-(4-clorofényl)-1,3-thiazol-4-yl]méthyl]sulfanyl]-4-[4-(2-hydroxyéthoxy)phényl]pyridine-3,5-dicarbonitrile
capadenosón	2-amino-6-([2-(4-clorofenil)-1,3-tiazol-4-il]metil)sulfanil]-4-[4-(2-hidroxiétoxi)fenil]piridina-3,5-dicarbonitrilo

C₂₅H₁₈ClN₅O₂S₂**catramilastum**


catramilast

1-((2*S*)-2-[3-(cyclopropylmethoxy)-4-methoxyphenyl]propyl)-1,3-dihydro-2*H*-imidazol-2-one

catramilast

1-[(2*S*)-2-[3-(cyclopropylméthoxy)-4-méthoxyphényl]propyl]-1,3-dihydro-2*H*-imidazol-2-one

catramilast

1-((2*S*)-2-[3-(ciclopropilmetoxi)-4-metoxifenil]propil)-1,3-dihidro-2*H*-imidazol-2-onaC₁₇H₂₂N₂O₃**cediranibum**


cediranib

4-[(4-fluoro-2-methyl-1*H*-indol-5-yl)oxy]-6-methoxy-7-[3-(pyrrolidin-1-yl)propoxy]quinazoline

cédiranib

4-[(4-fluoro-2-méthyl-1*H*-indol-5-yl)oxy]-6-méthoxy-7-[3-(pyrrolidin-1-yl)propoxy]quinazoline

cediranib

4-[(4-fluoro-2-metil-1*H*-indol-5-il)oxi]-6-metoxi-7-[3-(pirrolidin-1-il)=propoxi]quinazolinaC₂₅H₂₇FN₄O₃**denibulinum**

denibulin


methyl [5-((4-((2*S*)-2-aminopropanamido)phenyl)sulfanyl)-1*H*-benzimidazol-2-yl]carbamate

dénibuline

[5-[[4-[[((2*S*)-2-aminopropanamido)phényl]sulfanyl]-1*H*-benzimidazol-2-yl]carbamate de méthyle

denibulina

[5-[[4-[[((2*S*)-2-aminopropanamido]fenil)sulfanil]-1*H*-bencimidazol-2-il]carbamato de metilo

C₁₈H₁₉N₅O₃S


dexelvucitabinum
dexelvucitabine

4-amino-5-fluoro-1-[(2*R*,5*S*)-5-(hydroxymethyl)-2,5-dihydrofuran-2-yl]pyrimidin-2(1*H*)-one

dexelvucitabine

(+) -4-amino-5-fluoro-1-[(2*R*,5*S*)-5-(hydroxyméthyl)-2,5-dihydrofuran-2-yl]pyrimidin-2(1*H*)-one

dexelvucitabina

(+) -4-amino-5-fluoro-1-[(2*R*,5*S*)-5-(hidroximetil)-2,5-dihydrofuran-2-il]pirimidin-2(1*H*)-onaC₉H₁₀FN₃O₃

efungumabum*
efungumab

immunoglobulin scFv fragment, anti-(heat shock protein 90 homolog from *Candida albicans* (yeast)), methionylalanyl-[human monoclonal HSP90mab VH domain (120 residues)]-tris[(tetraglycyl)seryl]-[human monoclonal HSP90mab V-KAPPA domain (107 residues)]-arginyl-trialanyl-leucyl-glutamyl]-hexahistidine

éfungumab

immunoglobuline fragment scFv, anti-(homologue de la protéine de choc thermique 90 de *Candida albicans* (levure)), methionylalanyl-[domaine VH (120 résidus) de l'anticorps monoclonal humain HSP90mab]-tris[(tetraglycyl)seryl]-[domaine V-KAPPA (107 résidus) de l'anticorps monoclonal humain HSP90mab]-[arginyl-trialanyl-leucyl-glutamyl]-hexahistidine

efungumab

immunoglobulina fragmento scFv, anti-(homólogo de la proteína de choc térmico 90 de *Candida albicans*), metionilalanil-[dominio VH (120 restos) del anticuerpo monoclonal humano HSP90mab]-tris[(tetraglicil)seril]-[dominio V-KAPPA (107 restos) del anticuerpo monoclonal humano HSP90mab]-[arginil-trialanil-leucil-glutamil]-hexahistidina

```

MAEVQLVES GAEVKPPGES LRISCKGSGC IISSYWISWV RQMPGKGLEW
MGKIDPGDSY INYSPFQGH VTISADKSIN TAYLQWNSLK ASDTAMYICA
RGGDRDFGDSF DYWGQGLTIV VSSGGGGSGG GSGGGGSDV VMTQSPSFLS
AFVGDRIITIT CRASSGISRY LAWYQQAPGK APKLLIYAAS TLQTGVPSRF
SGSGSGTEFT LTINSLQPED FATYQCQLN SYPLTFGGGT KVDIKRAAA
LEhhhhhh

```

eocalcitolum


eocalcitol

(1*S*,3*R*,5*Z*,7*E*,23*E*)-1-fluoro-26,27-dihomo-9,10-secocolesta-5,7,10(19),16,23-pentaene-3,25-diol

éocalcitol

(1*R*,5*S*)-3-[(1*Z*)-2-[(3*aS*,4*E*,7*aS*)-1-[(1*S*,3*E*)-5-éthyl-5-hydroxy-1-méthylhept-3-ényl]-7*a*-méthyl-3,3*a*,5,6,7,7*a*-hexahydro-4*H*-indén-4-ylidène]éthylidène]-5-fluoro-4-méthylidénecyclohexanol

eocalcitol

(1*S*,3*R*,5*Z*,7*E*,23*E*)-1-fluoro-26,27-dihomo-9,10-secocolesta-5,7,10(19),16,23-pentaeno-3,25-diolC₂₉H₄₃FO₂**elsibucolum**


elsibucol

4-[4-[(2-[[3,5-di-*tert*-butyl-4-hydroxyphenyl]sulfanyl]propan-2-yl)sulfanyl]-2,6-di-*tert*-butylphenoxy]butanoic acid

elsibucol

acide 4-[4-[[1-[[3,5-bis(1,1-diméthyléthyl)-4-hydroxyphényl]sulfanyl]-1-méthyléthyl]sulfanyl]-2,6-bis(1,1-diméthyléthyl)phénoxy]butanoïque

elsibucol

ácido 4-[4-[(2-[[3,5-di-*terc*-butil-4-hidroxifenil]sulfanil]propan-2-il)sulfanil]-2,6-di-*terc*-butilfenoxi]butanoicoC₃₅H₅₄O₄S₂**epoetinum theta**

epoetin theta



human erythropoietin-(1-165)-peptide, glycoform θ


époétine thêta

érythropoïétine humaine-(1-165)-peptide, glycoforme θ

epoetina zeta

eritropoyetina humana-peptido-(1-165), glicofoma θ C₈₀₉H₁₃₀₁N₂₂₉O₂₄₀S₅

ferroquinum ferroquine	<i>N'</i> -(7-chloroquinolin-4-yl)- <i>N,N</i> -dimethyl- <i>C,C'</i> -(ferrocene-1,2-diyl)=dimethanamine
ferroquine	<i>N'</i> -(7-chloroquinoléin-4-yl)- <i>N,N</i> -diméthyl- <i>C,C'</i> -(férocène-1,2-diyl)=diméthanamine
ferroquina	<i>N'</i> -(7-cloroquinolin-4-il)- <i>N,N</i> -dimetil- <i>C,C'</i> -(ferroceno-1,2-diil)=dimetanamina
	$C_{23}H_{24}ClFeN_3$
	
fluticasonum furoas fluticasone furoate	6 α ,9-difluoro-17[[[(fluoromethyl)sulfanyl]carbonyl]-11 β -hydroxy-16 α -methyl-3-oxoandrosta-1,4-dien-17 α -yl] furan-2-carboxylate
furoate de fluticasone	furane-2-carboxylate de 6 α ,9-difluoro-17-[[[(fluorométhyl)sulfanyl]=carbonyl]-11 β -hydroxy-16 α -méthyl-3-oxoandrosta-1,4-dién-17 α -yle
furoato de fluticasona	furano-2-carboxilato de 6 α ,9-difluoro-17-[[[(fluorometil)sulfanil]=carbonil]-11 β -hidroxi-16 α -metil-3-oxoandrosta-1,4-dien-17 α -ilo
	$C_{27}H_{29}F_3O_6S$
	
fosalvudinum tidoxilum fosalvudine tidoxil	(2 <i>RS</i>)-2-(decyloxy)-3-[(dodecyl)sulfanyl]propyl [(2 <i>R</i> ,3 <i>S</i> ,5 <i>R</i>)-3-fluoro-5-(5-methyl-2,4-dioxo-3,4-dihydropyrimidin-1(2 <i>H</i>)-yl)tetrahydrofuran-2-yl]methyl hydrogen phosphate
fosalvudine tidoxil	hydrogénophosphate de (2 <i>RS</i>)-2-(décyloxy)-3-(dodécylsulfanyl)=propyle et de [(2 <i>R</i> ,3 <i>S</i> ,5 <i>R</i>)-3-fluoro-5-(5-méthyl-2,4-dioxo-3,4-dihydropyrimidin-1(2 <i>H</i>)-yl)tétrahydrofuran-2-yl]méthyle
fosalvudina tidoxilo	hidrógenofosfato de (2 <i>RS</i>)-2-(deciloxi)-3-[(dodecil)sulfanil]propilo y [(2 <i>R</i> ,3 <i>S</i> ,5 <i>R</i>)-3-fluoro-5-(5-metil-2,4-dioxo-3,4-dihidropirimidin-1(2 <i>H</i>)-il)tetrahidrofuran-2-il]metilo

C₃₅H₆₄FN₂O₈PS**gamithromycinum**

gamithromycin


(2*R*,3*S*,4*R*,5*S*,8*R*,10*R*,11*R*,12*S*,13*S*,14*R*)-13-[(2,6-dideoxy-3-*C*-methyl-3-*O*-methyl- α -*L*-ribo-hexopyranosyl)oxy]-2-ethyl-3,4,10-trihydroxy-3,5,8,10,12,14-hexamethyl-7-propyl-11-[[3,4,6-trideoxy-3-(dimethylamino)- β -*D*-xylo-hexopyranosyl]oxy]-1-oxa-7-azacyclopentadecan-15-one

gamithromycin

(2*R*,3*S*,4*R*,5*S*,8*R*,10*R*,11*R*,12*S*,13*S*,14*R*)-13-[(2,6-didésoxy-3-*C*-méthyl-3-*O*-méthyl- α -*L*-ribo-hexopyranosyl)oxy]-2-éthyl-3,4,10-trihydroxy-3,5,8,10,12,14-hexaméthyl-7-propyl-11-[[3,4,6-tridésoxy-3-(diméthylamino)- β -*D*-xylo-hexopyranosyl]oxy]-1-oxa-7-azacyclopentadécan-15-one

gamitromicina

(2*R*,3*S*,4*R*,5*S*,8*R*,10*R*,11*R*,12*S*,13*S*,14*R*)-13-[(2,6-didesoxi-3-*C*-metil-3-*O*-metil- α -*L*-ribo-hexopiranosil)oxi]-2-etil-3,4,10-trihidroxi-3,5,8,10,12,14-hexametil-7-propil-11-[[3,4,6-tridesoxi-3-(dimetilamino)- β -*D*-xylo-hexopiranosil]oxi]-1-oxa-7-azaciclopentadecan-15-ona

C₄₀H₇₆N₂O₁₂**ilepatrilum**

ilepatril


(4*S*,7*S*,12*bR*)-7-[(2*S*)-2-(acetylsulfanyl)-3-methylbutanamido]-6-oxo-1,2,3,4,6,7,8,12*b*-octahydropyrido[2,1-*a*][2]benzazepine-4-carboxylic acid

ilépatril

acide (4*S*,7*S*,12*bR*)-7-[[2*S*)-2-(acétylsulfanyl)-3-méthylbutanoyl]=amino]-6-oxo-1,2,3,4,6,7,8,12*b*-octahydropyrido[2,1-*a*][2]=benzazépine-4-carboxylique

ilepatrilo

ácido (4*S*,7*S*,12*bR*)-7-[[2*S*)-2-(acetilsulfanil)-3-metilbutanoil]amino]-6-oxo-1,2,3,4,6,7,8,12*b*-octahidropirido[2,1-*a*][2]benzazepina-4-carboxílico

C₂₂H₂₈N₂O₅S

imisopasemum manganum
imisopasem manganese


(PBPY-7-11-2344'3')-dichloro[(4aR,13aR,17aR,21aR)-1,2,3,4,4a,5,6,12,13,13a,14,15,16,17,17a,18,19,20,21,21a-icosahydro-7,11-(azeno)dibenzo[*b,h*][1,4,7,10]=tetraazacycloheptadecine-κ⁴N⁶,N¹³,N¹⁸,N²¹,N²²]manganese

imisopasem manganèse

(PBPY-7-11-2344'3')-dichloro[(4aR,13aR,17aR,21aR)-1,2,3,4,4a,5,6,12,13,13a,14,15,16,17,17a,18,19,20,21,21a-icosahydro-7,11-nitrilo-7H-dibenzo[*b,h*][1,4,7,10]=tétraazacycloheptadécine-κ⁴N⁶,κN¹³,κN¹⁸,κN²¹,κN²²]manganèse

imisopasem manganeso

(PBPY-7-11-2344'3')-dicloro[(4aR,13aR,17aR,21aR)-1,2,3,4,4a,5,6,12,13,13a,14,15,16,17,17a,18,19,20,21,21a-icosahidro-7,11-(azeno)dibenzo[*b,h*][1,4,7,10]=tetraazacycloheptadecino-κ⁴N⁶,N¹³,N¹⁸,N²¹,N²²]manganeso

C₂₁H₃₅Cl₂MnN₅

inakalantum
inakalant


tert-butyl (2-[7-[(2S)-3-(4-cyanophenoxy)-2-hydroxypropyl]-9-oxa-3,7-diazabicyclo[3.3.1]nonan-3-yl]ethyl)carbamate

inakalant

[2-[7-[(2S)-3-(4-cyanophénoxy)-2-hydroxypropyl]-9-oxa-3,7-diazabicyclo[3.3.1]non-3-yl]éthyl]carbamate de 1,1-diméthyléthyle

inakalant

(2-[7-[(2S)-3-(4-cianofenoxi)-2-hidroxipropil]-9-oxa-3,7-diazabicyclo[3.3.1]nonan-3-il]etil)carbamato de *terc*-butilo

C₂₃H₃₄N₄O₅

lapaquistatum


lapaquistat

(1-[[[(3*R*,5*S*)-1-(3-hydroxy-2,2-diméthylpropyl)-7-chloro-5-(2,3-diméthoxyphényl)-2-oxo-1,2,3,5-tétrahydro-4,1-benzoxazépin-3-yl]acétyl]piperidin-4-yl]acétique acid

lapaquistat

acide (1-[[[(3*R*,5*S*)-1-(3-hydroxy-2,2-diméthylpropyl)-7-chloro-5-(2,3-diméthoxyphényl)-2-oxo-1,2,3,5-tétrahydro-4,1-benzoxazépin-3-yl]acétyl]piperidin-4-yl]acétique

lapaquistat

ácido (1-[[[(3*R*,5*S*)-1-[3-hidroxi-2,2-dimetilpropil]]-7-cloro-5-(2,3-dimetoxifenil)-2-oxo-1,2,3,5-tetrahidro-4,1-benzoxazépin-3-il]acétil]piperidin-4-il]acéticoC₃₁H₃₉ClN₂O₈**levonadifloxacinum**


levonadifloxacin

(5*S*)-9-fluoro-8-(4-hydroxypiperidin-1-yl)-5-méthyl-1-oxo-6,7-dihydro-1*H*,5*H*-benzo[*ij*]quinolizine-2-carboxylic acid

lévonadifloxacine

(-)-acide (5*S*)-9-fluoro-8-(4-hydroxypipéridin-1-yl)-5-méthyl-1-oxo-6,7-dihydro-1*H*,5*H*-benzo[*ij*]quinolizine-2-carboxylique

levonadifloxacino

ácido (5*S*)-9-fluoro-8-(4-hidroxipiperidin-1-il)-5-metil-1-oxo-6,7-dihidro-1*H*,5*H*-benzo[*ij*]quinolizina-2-carboxílicoC₁₉H₂₁FN₂O₄**lexatumumabum***

lexatumumab

immunoglobulin G1, anti-[human tumor necrosis factor receptor superfamily member 10B (TNFRSF10B, death receptor 5, TNF-related apoptosis-inducing ligand receptor 2, TRAIL-R2, CD262)] human monoclonal HGS-ETR2; gamma1 heavy chain (*Homo sapiens* VH-IGHG1) (224-213')-disulfide with lambda light chain (*Homo sapiens* V-LAMBDA- IGLC2); (230-230":233-233")-bisdisulfide dimer

lexatumumab immunoglobuline G1, anti-[membre 10B de la superfamille des récepteurs du facteur de nécrose tumorale humain (TNFRSF10B, death receptor 5, TRAIL-R2, CD262)] anticorps monoclonal humain HGS-ETR2; chaîne lourde gamma1 (*Homo sapiens* VH-IGHG1) (224-213')-disulfure avec la chaîne légère lambda (*Homo sapiens* V-LAMBDA- IGLC2); dimère (230-230":233-233")-bisdisulfure

lexatumumab inmunoglobulina G1, anti-[miembro 10B de la superfamilia de receptores del factor de necrosis tumoral humano (TNFRSF10B, death receptor 5, TRAIL-R2, CD262)] anticuerpo monoclonal humano HGS-ETR2; cadena pesada gamma1 (*Homo sapiens* VH-IGHG1) (224-213')-disulfuro con la cadena ligera lambda (*Homo sapiens* V-LAMBDA- IGLC2); dímero (230-230":233-233")-bisdisulfuro

C₆₃₄₆H₉₈₃₂N₁₇₂₀O₂₀₀₂S₄₂

Heavy chain / chaîne lourde / cadena pesada

EVQLVQSGGG	VERPGGSLRL	SCAASGFTFD	DYGMSWVRQA	PGKGLEWVSG	50
INWNGGSTGY	ADSVKGRVTI	SRDNAKNSLY	LQMNSLRAED	TAVYYCAKIL	100
GAGRGWYFDL	WGKGTTVTVS	SASTKGPSVF	PLAPSSKSTS	GGTAAALGCLV	150
KDYFPEPFTV	SWNSGALTSV	VHTFPAVLQS	SGLYSLSSVV	TVPSSSLGTQ	200
TYICNVNHKP	SNTKVDKRVK	PKSCDKTHTC	PPCPAPELLG	GPSVFLFPPK	250
PKDTLMSRT	PEVTCVVVDV	SHEDEPKVFN	WYVDGVEVHN	AKTKPREEQY	300
NSTYRVVSVL	TVLHQQDWLNG	KEYKCKVSNK	ALPAPIEKTI	SKARGQPREP	350
QVYTLPPSRE	EMTKNQVSLT	CLVKGFYPSD	IAVEWESNGQ	PENNYKTTTP	400
VLDSDGSFFL	YSKLTVDKSR	WQQGIVFSCS	VMHEALHNYH	TQKSLSLSPG	450

K

Lambda chain / chaîne lambda / cadena lambda

SSELTQDPAV	SVALGQTVRI	TCQGDLSRSY	YASWYQQKPG	QAPVLYIYGK	50
NNRPSGIPDR	FSGSSSGNTA	SLTITGAQAE	DEADYVCNSR	DSSGNHVVFV	100
GGTKLTVLQ	PKAAPSVTLF	PPSSEELQAN	KATLVCLISD	FYPGAVTVAW	150
KADSSPVKAG	VETTTPSKQS	NNKYAASSYL	SLTPEQWKSH	RSYSCQVTHE	200
GSTVEKTVAP	TECS				

Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro

22-96 22'-87" 22"-96" 22"-87" 136-195" 136"-195" 148-204 148"-204"
213'-224 213"-224" 230-230" 233-233" 265-325 265"-325" 371-429 371"-429"

lificiguatum

lificiguat

[5-(1-benzyl-1*H*-indazol-3-yl)furan-2-yl]methanol


lificiguat

[5-(1-benzyl-1*H*-indazol-3-yl)furan-2-yl]méthanol

lificiguat

[5-(1-bencil-1*H*-indazol-3-il)furan-2-il]metanol

C₁₉H₁₆N₂O₂



lobeglitazonum

lobeglitazone


(5*R*)-5-[[4-(2-[[6-(4-methoxyphenoxy)pyrimidin-4-yl]methylamino]ethoxy)phenyl]methyl]-1,3-thiazolidine-2,4-dione

lobéglitazone

(5*R*)-5-[4-[2-[[6-(4-méthoxyphénoxy)pyrimidin-4-yl]méthylamino]éthoxy]benzyl]thiazolidine-2,4-dione

lobeglitazona

(5*R*)-5-[4-(2-[[6-(4-metoxifenoxi)pirimidin-4-il]metilamino]etoxi)=bencil]-1,3-tiazolidina-2,4-diona

C₂₄H₂₄N₄O₅S**lorcaserinum**


lorcaserin

(1*R*)-8-chloro-1-methyl-2,3,4,5-tetrahydro-1*H*-3-benzazepine

lorcasérine

(1*R*)-8-chloro-1-méthyl-2,3,4,5-tétrahydro-1*H*-3-benzazépine

lorcaserina

(1*R*)-8-cloro-1-metil-2,3,4,5-tetrahydro-1*H*-3-benzazepinaC₁₁H₁₄ClN**mifamurtidum**


mifamurtide

2-[[*N*-[(2*R*)-[(2-acetamido-2,3-dideoxy-D-glucopyranos-3-yl)oxy]=propanoyl]-L-alanyl-D-isoglutaminyl-L-alanyl]amino]ethyl (2*R*)-2,3-bis(hexadecanoyloxy)propyl hydrogen phosphate

mifamurtide

hydrogénophosphate de 2-[[*N*-[(2*R*)-2-[(3*R*,4*R*,5*S*,6*R*)-3-(acétylamino)-2,5-dihydroxy-6-(hydroxyméthyl)tétrahydro-2*H*-pyran-4-yloxy]propanoyle]-L-alanyl-D-isoglutaminyle-L-alanyl]amino]éthyle et de (2*R*)-2,3-bis(hexanoyleoxy)propyle

mifamurtida

hidrógenofosfato de 2-[[*N*-[(2*R*)-2-[(3*R*,4*R*,5*S*,6*R*)-3-(acetilamino)-2,5-dihidroxi-6-(hidroximetil)tétrahidro-2*H*-piran-4-iloxi]propanoile]-L-alanile-D-isoglutaminile-L-alanile]amino]etile y de (2*R*)-2,3-bis(hexanoileoxi)propileC₅₉H₁₀₉N₆O₁₉P**migalastatum**

migalastat


(2*R*,3*S*,4*R*,5*S*)-2-(hydroxymethyl)piperidine-3,4,5-triol

migalastat

(+)-(2*R*,3*S*,4*R*,5*S*)-2-(hydroxyméthyl)pipéridine-3,4,5-triol

migalastat

(2*R*,3*S*,4*R*,5*S*)-2-(hidroximetil)piperidina-3,4,5-triol



mirodenafilum
mirodenafil



5-ethyl-2-(5-[[4-(2-hydroxyethyl)piperazin-1-yl]sulfonyl]-2-propoxyphenyl)-7-propyl-3,5-dihydro-4*H*-pyrrolo[3,2-*d*]pyrimidin-4-one

mirodénafil

5-éthyl-2-[5-[[4-(2-hydroxyéthyl)pipérazin-1-yl]sulfonyl]-2-propoxyphényl]-7-propyl-3,5-dihydro-4*H*-pyrrolo[3,2-*d*]pyrimidin-4-one

mirodenafilo

5-etil-2-(5-[[4-(2-hidroxietil)piperazin-1-il]sulfonyl]-2-propoxifenil)-7-propil-3,5-dihidro-4*H*-pirrolo[3,2-*d*]pirimidin-4-ona



motavizumabum*
motavizumab

immunoglobulin G1, anti-(human respiratory syncytial virus glycoprotein F) humanized monoclonal MEDI-524; gamma1 heavy chain [humanized VH (*Homo sapiens* FR/*Mus musculus* CDR)-*Homo sapiens*IGHG1] (223-213')-disulfide with kappa light chain [humanized V-KAPPA (*Homo sapiens* FR/*Mus musculus* CDR)-*Homo sapiens*IGKC]; (229-229":232-232")-bisdisulfide dimer

motavizumab

immunoglobuline G1, anti-(glycoprotéine de fusion du virus syncytial respiratoire humain) anticorps monoclonal humanisé MEDI-524; chaîne lourde gamma1 [VH humanisé (*Homo sapiens* FR/*Mus musculus* CDR)-*Homo sapiens*IGHG1] (223-213')-disulfure avec la chaîne légère kappa [V-KAPPA humanisé (*Homo sapiens* FR/*Mus musculus* CDR)-*Homo sapiens*IGKC]; dimère (229-229":232-232")-bisdisulfure

motavizumab

immunoglobulina G1, anti-(glicoproteína de fusión del virus sincitial respiratorio humano) anticuerpo monoclonal humanizado MEDI-524; cadena pesada gamma1 [VH humanizada (*Homo sapiens* FR/*Mus musculus* CDR)-*Homo sapiens*IGHG1] (223-213')-disulfuro con la cadena ligera kappa [V-KAPPA humanizada (*Homo sapiens* FR/*Mus musculus* CDR)-*Homo sapiens*IGKC]; (229-229":232-232")-bisdisulfide dimer

C₆₄₇₆H₁₀₀₁₄N₁₇₀₆O₂₀₀₈S₄₈ γ -1-Chain / Chaîne γ -1 / Cadena γ -1

QVTLRESGPA	LVKPTQTTLT	TCTFSGFSL	TAGMSVGWIR	QPPGKALEWL	50
ADLWDDKKH	YNPSLKDRLT	ISKDTSKNQV	VLKVTNMDPA	DTATYCARD	100
MIFNFYFDVW	GQGTTVTVSS	ASTKGPSVFP	LAPSSKSTSG	GTAALGCLVK	150
DYFPEPVTVS	WNSGALTSKV	HTFPAVLQSS	GLYSLSSVVT	VPSSSLGTQT	200
YICNVNHKPS	NTKVDKRVEP	KSCDKTHTCP	PCPAPELLGG	PSVFLFPPKP	250
KDTLMISRTP	EVTQVVDVDS	HEDPEVKFNW	YVDGVEVHNA	KTKPREEQYN	300
STYRVVSVLT	VLHODWLNKG	EYKCKVSNKA	LPAPIEKTIS	KAKGQPREPQ	350
VYTLPPSREE	MTKNQVSLTC	LVKGFYPSDI	AVEWESNGQP	ENNYKTTTPV	400
LDSDGSFFLY	SKLTVDKSRW	QQGNVFSCSV	MHEALHNYHT	QKSLSLSPGK	450

 κ Chain / Chaîne κ / Cadena κ

DIQMTQSPST	LSASVGDVRT	ITCSASSRVG	YMHWYQQKPG	KAPKLLIYDT	50
SKLASVPSR	FSGSGSGTEF	TLTISLQPD	DFATYICFPQ	SGYPTFFGG	100
TKVEIKRTVA	APSVFIFPPS	DEQLKSGTAS	VVCLLNNFYP	REAKVQWVKD	150
NALQSGNSQE	SVTEQDSKDS	TYSLSSLTTL	SKADYEKHKV	YACEVTHQGL	200
SSPVTKSPNR	GEC				213

Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro
 22-97 22'-97" 23-87 23'-87" 133-193 133'-193" 147-203 147'-203"
 213-223 213'-223" 229-229 232-232" 264-324 264'-324" 370-428 370'-428"

naproxcinodum

naproxcinod


4-(nitrooxy)butyl (2S)-2-(6-methoxynaphthalen-2-yl)propanoate

naproxcinod

(2S)-2-(6-méthoxynaphthalén-2-yl)propanoate de 4-(nitrooxy)butyle

naproxcinod

(2S)-2-(6-metoxinaftalen-2-il)propanoato de 4-(nitrooxi)butilo

C₁₈H₂₁NO₆**omriptolidum**

omriptolide


4-[[[(3bS,4aS,5aR,6R,6aS,7aS,7bS,8aS,8bS)-8b-methyl-6a-(propan-2-yl)-1-oxo-1,3,3b,4,4a,6,6a,7a,7b,8b,9,10-dodecahydrotrisoxireno=[4b,5:6,7:8a,9]phenanthro[1,2-c]furan-6-yl]oxy]-4-oxobutanoic acid

omriptolide

acide 4-[[[(3bS,4aS,5aR,6R,6aS,7aS,7bS,8aS,8bS)-8b-méthyl-6a-(1-méthyléthyl)-1-oxo-1,3,3b,4,4a,6,6a,7a,7b,8b,9,10-dodécahydrotrisoxiréno[4b,5:6,7:8a,9]phénanthro[1,2-c]furan-6-yl]=oxy]-4-oxobutanoïque

omriptolida

ácido 4-[[[(3bS,4aS,5aR,6R,6aS,7aS,7bS,8aS,8bS)-8b-metil-6a-(propan-2-il)-1-oxo-1,3,3b,4,4a,6,6a,7a,7b,8b,9,10-dodecahidrotrisoxireno[4b,5:6,7:8a,9]fenantro[1,2-c]furan-6-il]oxi]-4-oxobutanoico

C₂₄H₂₈O₉

pafuramidinum


pafuramidine

4,4'-(furan-2,5-diyl)bis(*N*-methoxybenzenecarboximidamide)

pafuramidine

4,4'-(furane-2,5-diyl)bis(*N*-méthoxybenzèncarboximidamide)

pafuramidina

4,4'-(furano-2,5-diil)bis(*N*-metoxibencenocarboximidamida)C₂₀H₂₀N₄O₃**pramiconazolom**


pramiconazole

1-(4-[4-[4-((2*S*,4*R*)-4-(2,4-difluorophenyl)-4-[(1*H*-1,2,4-triazol-1-yl)methyl]-1,3-dioxolan-2-yl)methoxy]phenyl]piperazin-1-yl]phenyl)-3-(propan-2-yl)imidazolidin-2-one

pramiconazole

(+) -1-[4-[4-[4-[(2*S*,4*R*)-4-(2,4-difluorophényl)-4-[(1*H*-1,2,4-triazol-1-yl)méthyl]-1,3-dioxolan-2-yl]méthoxy]phényl]pipérazin-1-yl]phényl]-3-(1-méthyléthyl)imidazolidin-2-one

pramiconazol

1-(4-[4-[4-((2*S*,4*R*)-4-(2,4-difluorofenil)-4-[(1*H*-1,2,4-triazol-1-il)metil]-1,3-dioxolan-2-il]metoxi]fenil]piperazin-1-il]fenil)-3-(propan-2-il)imidazolidin-2-onaC₃₅H₃₉F₂N₇O₄**prinaberelum**

prinaberel


7-ethenyl-2-(3-fluoro-4-hydroxyphenyl)-1,3-benzoxazol-5-ol

prinabérel


7-éthényl-2-(3-fluoro-4-hydroxyphényl)-1,3-benzoxazol-5-ol

prinaberel

7-etenil-2-(3-fluoro-4-hidroxifenil)-1,3-benzoxazol-5-ol

C₁₅H₁₀FNO₃

rilonaceptum* rilonacept	[653-glycine][human interleukin-1 receptor accessory protein-(1-339)-peptide (extracellular domain fragment) fusion protein with human type 1 interleukin-1 receptor-(5-316)-peptide (extracellular domain fragment) fusion protein with human immunoglobulin G1-(229 C-terminal residues)-peptide (Fc fragment)], (659-659':662-662')-bisdisulfide dimer
rilonacept	(659-659':662-662')-bisdisulfure du dimère de la [653-glycine][protéine accessoire du récepteur de l'interleukine-1 humaine-(1-339)-peptide (fragment du domaine extracellulaire) protéine de fusion avec le récepteur de type I humain de l'interleukine-1-(5-316)-peptide (fragment du domaine extracellulaire) protéine de fusion avec l'immunoglobuline G1 humaine-(229 résidus C-terminaux)-peptide (fragment Fc)]
rilonacept	(659-659':662-662')-bisdisulfuro del dímero de la [653-glicina][proteína accesoria del receptor de la interleukina-1 humana-(1-339)-péptido (fragmento del dominio extracelular) proteína de fusión con el receptor de tipo I humano de la interleukina-1-(5-316)-péptido (fragmento del dominio extracelular) proteína de fusión con la inmunoglobulina G1 humana-(229 restos C-terminales)-péptido (fragmento Fc)]
	C ₉₀₃₀ H ₁₃₉₃₂ N ₂₄₀₀ O ₂₆₇₀ S ₇₄
	Monomer / Monomère / Monómero
	SERCDWGLD TMRQIQVFED EPARIKCPFL EHFLLKFNYS AHSAGLTLIW 50
	YWTRQDRDLE EPINFRLPEN RISKEKDVLM FRPTLLNDTG NYTCMLRNTT 100
	YCSKVAFPLE VVQKDSFCFNS PMKLPVHKLY IEYGIQRITC PNVDGYFPSS 150
	VKPTITWYMG CYKIQNFNNV IPEGMNLISFL IALISNNGNY TCVVTPYENG 200
	RTPHLTRTLT VKVVGSPKNA VPPVIHSPND HVVYEKEPEGE ELLIPCTVVF 250
	SFLMDSRNEV WWTIDGKKPD DITIDVTINE SISHSRTEDE TRTQILSICK 300
	VTSDELKRSY VCHARSAKGE VAKAAVKQK VPAPRYTVEK CKEREKILL 350
	VSSANEIDVR PCPLNPNEHK GTITWKDDS KTFVSTEQAS RIHQHKEKLV 400
	FVPAKVEDSG HYYCVVRNNS YCLRIKISAK FVENEPNLCY NAQAIFKQKL 450
	PVAGDGLVC PYMEFFKNEN NELPKLQWYK DCKPLLLDNI HFSGVKDRLI 500
	VMNVAEKHRG NYTCHASYTY LGKQYPIITRV IEFITLLENK PTRPVIIVSPA 550
	NETMEVDLGS QIQLICNVTG QLSDIAYWKW NGSVIDEDDP VLGEDYYSVE 600
	NPANKRRSTL ITVLNISEIE SRFYKHPFPC FAKNTHGIDA AYIQLIYPVT 650
	NSGDKTHTCP PCPAPELLGG PSVFLFPPKP KDTLMISRTP EVTCVVVDVS 700
	HEDPEVKFNW YVDGVEVHNA KTKPREEQYN STYRVVSVLT VLHQDWLNGK 750
	EYKCKVSNKA LPAPIEKTIS KAKGQPREPQ VYTLPPSRDE LTKNQVSLTC 800
	LVKGFYPSDI AVEWESNGQP ENNYKTPPV LDSDGSFFLY SKLTVDKSRW 850
	QQGNVFSCSV MHEALHNNHYT QKSLSLSPGK 880
	Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro
	4-102 4-102' 27-94 27-94' 117-161 117-161' 140-192 140-192' 246-312
	246-312' 341-422 341-422' 362-414 362-414' 339-482 339-482' 460-514 460-514'
	566-630 566-630' 659-659' 662-662' 694-754 694-754' 800-858 800-858'
rosabulinum rosabulin	2-{3-[(4-cyanophenyl)methyl]indolizin-1-yl}-N-(3-methyl-1,2-thiazol-5-yl)-2-oxoacetamide
rosabuline	2-{3-(4-cyanobenzyl)indolizin-1-yl}-N-(3-méthylisothiazol-5-yl)-2-oxoacétamide
rosabulina	2-{3-[(4-cianofenil)metil]indolizin-1-il}-N-(3-metilisotiazol-5-il)-2-oxoacetamida

C₂₂H₁₆N₄O₂S

sagopilonum
sagopilone


(1*S*,3*S*,7*S*,10*R*,11*S*,12*S*,16*R*)-7,11-dihydroxy-8,8,12,16-tetramethyl-3-(2-methyl-1,3-benzothiazol-5-yl)-10-(prop-2-enyl)-4,17-dioxabicyclo[14.1.0]heptadecane-5,9-dione

sagopilone

(-)-(1*S*,3*S*,7*S*,10*R*,11*S*,12*S*,16*R*)-7,11-dihydroxy-8,8,12,16-tétraméthyl-3-(2-méthyl-1,3-benzothiazol-5-yl)-10-(prop-2-ényl)-4,17-dioxabicyclo[14.1.0]heptadécane-5,9-dione

sagopilona

(1*S*,3*S*,7*S*,10*R*,11*S*,12*S*,16*R*)-7,11-dihidroxi-8,8,12,16-tetrametil-3-(2-metil-1,3-benzotiazol-5-il)-10-(prop-2-enil)-4,17-dioxabicyclo[14.1.0]heptadecano-5,9-diona

C₃₀H₄₁NO₆S

sodelglitazarum
sodelglitazar


2-{4-[[[2-(2-fluoro-4-(trifluoromethyl)phenyl)-4-methyl-1,3-thiazol-5-yl)methyl]sulfonyl]-2-methylphenoxy}-2-methylpropanoic acid

sodelglitazar

acide 2-[4-[[[2-(2-fluoro-4-(trifluorométhyl)phényl)-4-méthyl-1,3-thiazol-5-yl]méthyl]sulfonyl]-2-méthylphénoxy]-2-méthylpropanoïque

sodelglitazar

ácido 2-[4-[[[2-(2-fluoro-4-(trifluorometil)fenil]-4-metil-1,3-tiazol-5-il)metil]sulfanil]-2-metilfenoxi]-2-metilpropanoico

C₂₃H₂₁F₄NO₃S₂

sofigatranum


sofigatran

propyl [(1S)-1-[(2S)-2-[(*trans*-4-aminocyclohexyl)méthyl]carbamoil]=pyrrolidine-1-carbonil]-2-méthyl-2-[(propan-2-yl)sulfanyl]propyl]=carbamate

sofigatran

[(1S)-1-[(2S)-2-[(*trans*-4-aminocyclohexyl)méthyl]carbamoil]=pyrrolidin-1-yl]carbonil]-2-méthyl-2-[(1-méthyléthyl)sulfanyl]propyl]=carbamate de propyle

sofigatrán

[(1S)-1-[(2S)-2-[(*trans*-4-aminociclohexil)metil]carbamoil]pyrrolidin-1-il]carbonil]-2-metil-2-[(propan-2-il)sulfanil]propil]carbamato de propiloC₂₄H₄₄N₄O₄S**succinobucolum**


succinobucol

4-{4-[(2-[(3,5-di(*tert*-butyl)-4-hydroxyphenyl)sulfanyl]propan-2-yl)sulfanyl]-2,6-di(*tert*-butyl)phenoxy]-4-oxobutanoic acid

succinobucol

acide 4-[4-[[1-[[3,5-bis(1,1-diméthyléthyl)-4-hydroxyphényl]sulfanyl]-1-méthyléthyl]sulfanyl]-2,6-bis(1,1-diméthyléthyl)phénoxy]-4-oxobutanoïque

succinobucol

ácido 4-[4-[(2-[(3,5-di(*tert*-butil)4-hidroxifenil]sulfanil]propan-2-il)sulfanil]-2,6-di(*tert*-butil)fenoxi]-4-oxobutanoicoC₃₅H₅₂O₅S₂**taribavirinum**

taribavirin



1-β-D-ribofuranosyl-1*H*-1,2,4-triazole-3-carboximidamide

taribavirine

1-β-D-ribofuranosyl-1*H*-1,2,4-triazole-3-carboximidamide

taribavirina

1-β-D-ribofuranosil-1*H*-1,2,4-triazol-3-carboximidamida

**tezampanelum**



tezampanel

(3*S*,4*aR*,6*R*,8*aR*)-6-[2-(1*H*-tetrazol-5-yl)ethyl]decahydroisoquinoline-3-carboxylic acid

tézampanel

(-)-acide (3*S*,4*aR*,6*R*,8*aR*)-6-[2-(1*H*-tétrazol-5-yl)éthyl]=
décahydroisoquinoléine-3-carboxylique

tezampanel

(-)-ácido (3*S*,4*aR*,6*R*,8*aR*)-6-[2-(1*H*-tetrazol-5-il)etil]=
decahidroisoquinolina-3-carboxílico**ticagrelorum**



ticagrelor

(1*S*,2*S*,3*R*,5*S*)-3-(7-([(1*R*,2*S*)-2-(3,4-difluorophenyl)cyclopropyl]=
amino)-5-(propylsulfanyl)-3*H*-[1,2,3]triazolo[4,5-*d*]pyrimidin-3-yl)-
5-(2-hydroxyethoxy)cyclopentane-1,2-diol

ticagrélor

(1*S*,2*S*,3*R*,5*S*)-3-[7-([(1*R*,2*S*)-2-(3,4-difluorophényl)cyclopropyl]=
amino]-5-(propylsulfanyl)-3*H*-[1,2,3]triazolo[4,5-*d*]pyrimidin-3-yl)-
5-(2-hydroxyéthoxy)cyclopentane-1,2-diol

ticagrelor

(1*S*,2*S*,3*R*,5*S*)-3-(7-([(1*R*,2*S*)-2-(3,4-difluorofenil)ciclopropil]amino)-
5-(propilsulfanil)-3*H*-[1,2,3]triazolo[4,5-*d*]pirimidin-3-il)-
5-(2-hidroxietoxi)ciclopentano-1,2-diol

tigapotidum

tigapotide


L-glutamyl-L-tryptophyl-L-glutamyl-L-threonyl-L-aspartyl-L-asparagyl-S-[(acetamido)methyl]-L-cysteinyl-L-glutamyl-L-threonyl-S-[(acetamido)methyl]-L-cysteinyl-L-threonyl-S-[(acetamido)methyl]-L-cysteinyl-L-tyrosyl-L-glutamyl-L-threonine

tigapotide

S^{37} - S^{40} , S^{42} -tris[(acétylamino)méthyl]bêta-microsémipoprotéine humaine (protéine PSP94 sécrétée par la prostate)-(31-45)-peptide

tigapotida

S^{37} - S^{40} , S^{42} -tris[(acetylaminometil]beta-microseminoproteina humana (proteina PSP94 secretada por la prostata)-(31-45)-péptido

 $C_{82}H_{119}N_{21}O_{34}S_3$


H-Glu-Trp-Gln-Thr-Asp-Asn-Cys-Glu-Thr-Cys-Thr-Cys-Tyr-Glu-Thr-OH

tipelukastum

tipelukast


4-(6-acetyl-3-[(4-acetyl-3-hydroxy-2-propylphenyl)sulfanyl]=propoxy)-2-propylphenoxy)butanoic acid

tipelukast

acide 4-[6-acétyl-3-[(4-acétyl-3-hydroxy-2-propylphényl)sulfanyl]=propoxy]-2-propylphénoxy)butanoïque

tipelukast

ácido 4-[6-acetil-3-[(4-acetil-3-hidroxi-2-propilfenil)sulfanil]=propoxi]-2-propilfenoxi)butanoico

 $C_{29}H_{38}O_7S$
**tomopenemum**

tomopenem


(4*R*,5*S*,6*S*)-3-(((3*S*,5*S*)-5-[(3*S*)-3-(carbamimidamidoacetamido)=pyrrolidine-1-carbonyl]-1-methylpyrrolidin-3-yl)sulfanyl)-6-[(1*R*)-1-hydroxyethyl]-4-methyl-7-oxo-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid

tomopénem

(-)-acide (4*R*,5*S*,6*S*)-3-[[[(3*S*,5*S*)-5-[[[(3*S*)-3-[(carbamimidoylamino)=acétyl]amino]pyrrolidin-1-yl]carbonyl]-1-méthylpyrrolidin-3-yl]=sulfanyl]-6-[(1*R*)-1-hydroxyéthyl]-4-méthyl-7-oxo-1-azabicyclo[3.2.0]=hept-2-ène-2-carboxylique

tomopenem

ácido (4*R*,5*S*,6*S*)-3-[[[(3*S*,5*S*)-5-[[[(3*S*)-3-(carbamimidamidoacetamido)pirrolidin-1-il]carbonil]-1-metilpirrolidin-3-il]sulfanil]-6-[(1*R*)-1-hidroxietil]-4-metil-7-oxo-1-azabicyclo[3.2.0]=hept-2-eno-2-carboxílico

C₂₃H₃₅N₇O₆S

tylvalosinum
tylvalosin


(4*R*,5*S*,6*S*,7*R*,9*R*,11*E*,13*E*,15*R*,16*R*)-15-[[[(6-deoxy-2,3-di-*O*-methyl-β-D-allopyranosyl)oxy]methyl]-6-[[3,6-dideoxy-4-*O*-[2,6-dideoxy-3-*C*-methyl-4-*O*-(3-methylbutanoyl)-α-*L*-ribo-hexopyranosyl]-3-(dimethylamino)-β-D-glucopyranosyl]oxy]-16-ethyl-5,9,13-trimethyl-2,10-dioxo-7-(2-oxoethyl)oxacyclohexadeca-11,13-dien-4-yl acetate

tylvalosine

(-)-acétate de (4*R*,5*S*,6*S*,7*R*,9*R*,11*E*,13*E*,15*R*,16*R*)-15-[[[(6-désoxy-2,3-di-*O*-méthyl-β-D-allopyranosyl)oxy]méthyl]-6-[[3,6-didésoxy-4-*O*-[2,6-didésoxy-3-*C*-méthyl-4-*O*-(3-méthylbutanoyl)-α-*L*-ribo-hexopyranosyl]-3-(diméthylamino)-β-D-glucopyranosyl]oxy]-16-éthyl-5,9,13-triméthyl-2,10-dioxo-7-(2-oxoéthyl)oxacyclohexadéca-11,13-dién-4-yle

tilvalosina

(-)-acetato de (4*R*,5*S*,6*S*,7*R*,9*R*,11*E*,13*E*,15*R*,16*R*)-15-[[[(6-desoxi-2,3-di-*O*-metil-β-D-alopiranosil)oxi]metil]-6-[[3,6-didesoxi-4-*O*-[2,6-didesoxi-3-*C*-metil-4-*O*-(3-metilbutanoil)-α-*L*-ribo-hexopiranosil]-3-(dimetilamino)-β-D-glucopiranosil]oxi]-16-etil-5,9,13-trimetil-2,10-dioxo-7-(2-oxoetil)oxaciclohexadeca-11,13-dien-4-ilo

C₅₃H₈₇NO₁₉

vabicaserinum
vabicaserin


(9*aR**,12*aS**)-4,5,6,7,9,9*a*,10,11,12,12*a*-decahydrocyclopenta[*c*][1,4]diazepino[6,7,1-*ij*]quinoline

vabicasérine

(-)-(9*aR**,12*aS**)-4,5,6,7,9,9*a*,10,11,12,12*a*-décahydrocyclopenta[*c*][1,4]diazepino[6,7,1-*ij*]quinoléine

vabicaserina

(-)-(9*aR**,12*aS**)-4,5,6,7,9,9*a*,10,11,12,12*a*-decahidrociclopenta[*c*][1,4]diazepino[6,7,1-*ij*]quinolina

C₁₅H₂₀N₂

or enantiomer, (-)-isomer
ou énantiomère, (-)-isomère
o enantiómero, (-)-isómero

vaptadinum


vaptadine

5,6-dihydrospiro(imidazo[2,1-*b*][3]benzazepine-11,4'-piperidine)-3-carboxamide

vaptadine

5,6-dihydrospiro[11*H*-imidazo[2,1-*b*][3]benzazépine-11,4'-pipéridine]-3-carboxamide

vaptadina

5,6-dihidrospiro(11*H*-imidazo[2,1-*b*][3]benzazepina-11,4'-piperidina)-3-carboxamidaC₁₇H₂₀N₄O**veliflaponum**


veliflapon

(2*R*)-cyclopentyl{4-[(quinolin-2-yl)methoxy]phenyl}acetic acid

véliflapon

(+)-acide (2*R*)-cyclopentyl[4-(quinoléin-2-ylméthoxy)phényl]acétique

veliflapón

(+)-ácido (2*R*)-ciclopentil[4-(quinolin-2-ilmetoxi)fenil]acéticoC₂₃H₂₃NO₃**volinanserinum**

volinanserin



(2*R*)-(2,3-dimethoxyphenyl){1-[2-(4-fluorophenyl)ethyl]piperidin-4-yl}=methanol

volinansérine

(+)-(2*R*)-(2,3-diméthoxyphényl)[1-[2-(4-fluorophényl)éthyl]pipéridin-4-yl]méthanol

volinanserina


(+)-(2*R*)-(2,3-dimetoxifenil)[1-[2-(4-fluorofenil)etil]piperidin-4-il]metanol



**AMENDMENTS TO PREVIOUS LISTS
MODIFICATIONS APPORTÉES AUX LISTES ANTÉRIEURES
MODIFICACIONES A LAS LISTAS ANTERIORES**

Recommended International Non Proprietary Names (Rec. INN): List 53
Dénominations communes internationales recommandées (DCI Rec.): Liste 53
Denominaciones Comunes Internacionales recomendadas (DCI Rec.): Lista 53
(WHO Drug Information, Vol. 19, No. 1, 2005)

- | | | |
|-------|---|--|
| p. 80 | <i>delete/supprimer/suprímase</i>
gantacurium chloridum | <i>insert/insérer/insértese</i>
gantacurii chloridum |
| p. 88 | panitumumabun
panitumumab
panitumumab
panitumumab | <i>replace the molecular formula by the following</i>
<i>remplacer la formule brute par la suivante</i>
<i>sustitúyase la fórmula molecular por la siguiente</i> |



- | | | |
|-------|---------------------------------|--|
| p. 88 | pelitinibum
pelitinib | <i>sustitúyase el nombre químico por el siguiente:</i>
<i>(2E)-N-[3-ciano-4-[(3-cloro-4-fluorofenil)amino]-7-etoxiquinolin-6-il]-</i>
<i>4-(dimetilamino)-2-butenamina</i> |
|-------|---------------------------------|--|

Recommended International Non Proprietary Names (Rec. INN): List 55
Dénominations communes internationales recommandées (DCI Rec.): Liste 55
Denominaciones Comunes Internacionales recomendadas (DCI Rec.): Lista 55
(WHO Drug Information, Vol. 20, No. 1, 2006)

- | | | |
|-------|--------------------------------|--------------------------------|
| p. 45 | <i>suprimáse</i>
nebicapone | <i>insértese</i>
nebicapona |
|-------|--------------------------------|--------------------------------|

* Electronic structure available on Mednet: <http://mednet.who.int/>
 * Structure électronique disponible sur Mednet: <http://mednet.who.int/>
 * Estructura electrónica disponible en Mednet: <http://mednet.who.int/>

Procedure and Guiding Principles / Procédure et Directives / Procedimientos y principios generales

The text of the *Procedures for the Selection of Recommended International Nonproprietary Names for Pharmaceutical Substances* and *General Principles for Guidance in Devising International Nonproprietary Names for Pharmaceutical Substances* will be reproduced in proposed INN lists only.

Les textes de la *Procédure à suivre en vue du choix de dénominations communes internationales recommandées pour les substances pharmaceutiques* et des *Directives générales pour la formation de dénominations communes internationales applicables aux substances pharmaceutiques* seront publiés seulement dans les listes des DCI proposées.

El texto de los *Procedimientos de selección de denominaciones comunes internacionales recomendadas para las sustancias farmacéuticas* y de los *Principios generales de orientación para formar denominaciones comunes internacionales para sustancias farmacéuticas* aparece solamente en las listas de DCI propuestas.